GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Healios KK (TSE:4593) » Definitions » EV-to-EBIT

Healios KK (TSE:4593) EV-to-EBIT : -10.64 (As of Mar. 04, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Healios KK EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Healios KK's Enterprise Value is 円26,979.9 Mil. Healios KK's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was 円-2,536.0 Mil. Therefore, Healios KK's EV-to-EBIT for today is -10.64.

The historical rank and industry rank for Healios KK's EV-to-EBIT or its related term are showing as below:

TSE:4593' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.06   Med: -20.55   Max: -2.29
Current: -10.64

During the past 11 years, the highest EV-to-EBIT of Healios KK was -2.29. The lowest was -67.06. And the median was -20.55.

TSE:4593's EV-to-EBIT is ranked worse than
100% of 454 companies
in the Biotechnology industry
Industry Median: 7.005 vs TSE:4593: -10.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Healios KK's Enterprise Value for the quarter that ended in Jun. 2024 was 円14,350.7 Mil. Healios KK's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was 円-2,536.0 Mil. Healios KK's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -17.67%.


Healios KK EV-to-EBIT Historical Data

The historical data trend for Healios KK's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healios KK EV-to-EBIT Chart

Healios KK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.62 -18.47 -3.47 -3.46 -6.06

Healios KK Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.26 -3.46 -3.50 -5.66 -

Competitive Comparison of Healios KK's EV-to-EBIT

For the Biotechnology subindustry, Healios KK's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Healios KK's EV-to-EBIT falls into.



Healios KK EV-to-EBIT Calculation

Healios KK's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=26979.860/-2536
=-10.64

Healios KK's current Enterprise Value is 円26,979.9 Mil.
Healios KK's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,536.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healios KK  (TSE:4593) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Healios KK's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-2536/14350.7
=-17.67 %

Healios KK's Enterprise Value for the quarter that ended in Jun. 2024 was 円14,350.7 Mil.
Healios KK's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,536.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healios KK EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Healios KK's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Healios KK Business Description

Traded in Other Exchanges
Address
World Trade Center Bldg. 15th Floor, 2-4-1 Hamamatsucho, Minato-ku, Tokyo, JPN, 105-6115
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy.

Healios KK Headlines

No Headlines